SCHEMBL5203388

SCHEMBL5203388

Cc1ccc(S(=O)(=O)N(C)C(=O)C2CCC(c3nc(-c4cccc(C(F)(F)F)c4)c[nH]3)CC2)cc1

nearest known ligand 0.40

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
USP2 O75604 1/20 0.40
ALDH1A1 P00352 1/20 0.40
KCNH2 Q12809 1/20 0.40
SOS1 Q07889 2/20 0.38
RORC P51449 4/20 0.37
PTGS2 P35354 1/20 0.36
KDM1A O60341 1/20 0.36
MAOA P21397 1/20 0.36
MAOB P27338 1/20 0.36
UCHL1 P09936 1/20 0.36
TRPV4 Q9HBA0 1/20 0.36
ADORA1 P30542 1/20 0.36
RAF1 P04049 1/20 0.35
L3MBTL1 Q9Y468 2/20 0.35
MEN1 O00255 1/20 0.35
KMT2A Q03164 1/20 0.35
DHODH Q02127 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5208474 0.84 KCNH2 (0.44) USP2KCNH2KDM1AMAOAMAOB
SCHEMBL5202968 0.84 KCNH2 (0.44) USP2KCNH2KDM1AMAOAMAOB
SCHEMBL5209708 0.79 KCNH2 (0.44) KCNH2SOS1KDM1AMAOAMAOB
SCHEMBL5206565 0.79 KCNH2 (0.47) ALDH1A1KCNH2KDM1AMAOAMAOB
SCHEMBL14608992 0.79 KCNH2 (0.47) ALDH1A1KCNH2KDM1AMAOAMAOB
SCHEMBL5205158 0.79 KCNH2 (0.47) ALDH1A1KCNH2KDM1AMAOAMAOB
SCHEMBL5210403 0.78 SOS1 (0.45) ALDH1A1KCNH2SOS1KDM1AMAOA
SCHEMBL5207210 0.78 KDM1A (0.55) KCNH2KDM1AMAOAMAOBMEN1
SCHEMBL5202992 0.77 KCNH2 (0.46) KCNH2KDM1AMAOAMAOBMEN1
SCHEMBL5203000 0.77 KCNH2 (0.46) KCNH2KDM1AMAOAMAOBMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1306085-B1 2-Cyclohexyl-4-phenyl-1H-imidazole derivatives as ligands for the neuropeptide Y5 receptor NEUROGEN CORP (US) 2007-02-14 EP claimed
US-7034034-B2 Substituted 2-cyclohexyl-4-phenyl-1H-imidazole derivatives NEUROGEN CORPORATION (US) 2006-04-25 US claimed
WO-2003104255-A2 SUBSTITUTED 2-CYCLOHEXYL-4-PHENYL-1H-IMIDAZOLE DERIVATIVES NEUROGEN CORPORATION (US) 2003-12-18 WO claimed
US-20030144290-A1 Substituted 2-cyclohexyl-4-phenyl-1H-imidazole derivatives NEUROGEN CORPORATION 2003-07-31 US claimed
EP-1306085-A1 2-Cyclohexyl-4-phenyl-1H-imidazole derivatives as ligands for the neuropeptide Y5 receptor Neurogen Corporation (US) 2003-05-02 EP claimed
EP-1306085-B1 2-Cyclohexyl-4-phenyl-1H-imidazole derivatives as ligands for the neuropeptide Y5 receptor NEUROGEN CORP (US) 2007-02-14 EP disclosed
US-7034034-B2 Substituted 2-cyclohexyl-4-phenyl-1H-imidazole derivatives NEUROGEN CORPORATION (US) 2006-04-25 US disclosed
WO-2003104255-A2 SUBSTITUTED 2-CYCLOHEXYL-4-PHENYL-1H-IMIDAZOLE DERIVATIVES NEUROGEN CORPORATION (US) 2003-12-18 WO disclosed
US-20030144290-A1 Substituted 2-cyclohexyl-4-phenyl-1H-imidazole derivatives NEUROGEN CORPORATION 2003-07-31 US disclosed
EP-1306085-A1 2-Cyclohexyl-4-phenyl-1H-imidazole derivatives as ligands for the neuropeptide Y5 receptor Neurogen Corporation (US) 2003-05-02 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030144290-A1 Substituted 2-cyclohexyl-4-phenyl-1H-imidazole derivatives NPY5R, NPY4R, NPY1R USP2 4052/4885ALDH1A1 4260/4885KCNH2 1937/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.